At the highest doses, retatrutide seems to promise more significant weight loss than existing GLP-1s on the market but as dosage increases, so does the risk of side effects, mostly mild-to-moderate gastrointestinal issues, although one case of pancreatitis occurred in a patient on the 12mg dose during the phase II trial
These are some general solutions, but an individualized approach is best
One of our doctors will review your answers, why you want to switch, and current health
Obes Surg 28:35533558 Bonnet JB et al (2024) Semaglutide 2.4 mg/wk for weight loss in patients with severe obesity and with or without a history of bariatric surgery
Subclinical kidney injury before and 1 year after bariatric surgery among adolescents with severe obesity
Even the moderate 8 mg dose produced 21.1% reduction, which matches the best results seen with Tirzepatide at its maximum 15 mg dose